CORE A (Administration and Informatics) The Administrative Core is responsible for program planning and evaluation, operations management, organization of meetings, financial stewardship, and informatics services. Key Core A functions are to: ?Provide scientific and administrative oversight to all components of the Consortium. ?Coordinate communication and organize meetings between CRC investigators, staff, DSMB, external and internal advisory boards, ?Execute effective planning and evaluation systems to monitor program performance and efficiency in regards to resource management. ?Monitor for compliance with NIH, NCI, FDA, DHHS, and participating organizations, and render reports concerning such monitoring. Monitor use of human subjects, animal subjects, and tissue specimens. ?Develop and maintain specific policies and procedures to ensure the quality and confidentiality of all CRC data and associated information management systems. Maintain ongoing research into the enhancement of said policies to ensure compliance with evolving regulatory and legislative requirements. ?Manage grants/contracts, perform fiscal oversight /management, and disburse funds. ?Provide information management systems, including clinical, basic science, and administrate data collection, storage, and analysis instruments. ?Expand current information management systems to incorporate new data sets and data management requirements. ?Provide the community and CLL patients specifically, with information regarding CRC research activities and general OIL educational materials.
The primary objective of Core A is to enable the efficient and effective operation and coordination of consortium-wide projects and cores. This objective is motivated by the CRCs overall mission to help develop curative strategies for patients with Chronic Lymphocytic Leukemia.
|Barr, Paul M; Robak, Tadeusz; Owen, Carolyn et al. (2018) Sustained efficacy and detailed clinical follow-up of first-line ibrutinib treatment in older patients with chronic lymphocytic leukemia: extended phase 3 results from RESONATE-2. Haematologica 103:1502-1510|
|Kondo, K; Shaim, H; Thompson, P A et al. (2018) Ibrutinib modulates the immunosuppressive CLL microenvironment through STAT3-mediated suppression of regulatory B-cell function and inhibition of the PD-1/PD-L1 pathway. Leukemia 32:960-970|
|Hasan, Md Kamrul; Yu, Jian; Widhopf 2nd, George F et al. (2018) Wnt5a induces ROR1 to recruit DOCK2 to activate Rac1/2 in chronic lymphocytic leukemia. Blood 132:170-178|
|Ten Hacken, Elisa; Valentin, Rebecca; Regis, Fara Faye D et al. (2018) Splicing modulation sensitizes chronic lymphocytic leukemia cells to venetoclax by remodeling mitochondrial apoptotic dependencies. JCI Insight 3:|
|Gribben, John G (2018) How and when I do allogeneic transplant in CLL. Blood 132:31-39|
|Sivina, Mariela; Werner, Lillian; Rassenti, Laura et al. (2018) Dynamic changes in CCL3 and CCL4 plasma concentrations in patients with chronic lymphocytic leukaemia managed with observation. Br J Haematol 180:597-600|
|Ott, Christopher J; Federation, Alexander J; Schwartz, Logan S et al. (2018) Enhancer Architecture and Essential Core Regulatory Circuitry of Chronic Lymphocytic Leukemia. Cancer Cell 34:982-995.e7|
|Balatti, Veronica; Tomasello, Luisa; Rassenti, Laura Z et al. (2018) miR-125a and miR-34a expression predicts Richter syndrome in chronic lymphocytic leukemia patients. Blood 132:2179-2182|
|Vangapandu, Hima V; Chen, Huiqin; Wierda, William G et al. (2018) Proteomics profiling identifies induction of caveolin-1 in chronic lymphocytic leukemia cells by bone marrow stromal cells. Leuk Lymphoma 59:1427-1438|
|Yu, Jian; Chen, Yun; Chen, Liguang et al. (2018) Cirmtuzumab inhibits ibrutinib-resistant, Wnt5a-induced Rac1 activation and proliferation in mantle cell lymphoma. Oncotarget 9:24731-24736|
Showing the most recent 10 out of 562 publications